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Abstract
Background: Dementia risk in women is higher than in men, but the molecular neuropathology of this gender
difference remains poorly defined. In this study, we used unbiased, discovery-driven quantitative proteomics to assess
the molecular basis of gender influences on risk of Alzheimer’s disease with cerebrovascular disease (AD + CVD).
Results: We detected modulation of several redox proteins in the temporal lobe of AD + CVD subjects, and we
observed sex-specific alterations in the white matter (WM) and mitochondria proteomes of female patients. Functional
proteomic analysis of AD + CVD brain tissues revealed increased citrullination of arginine and deamidation of
glutamine residues of myelin basic protein (MBP) in female which impaired degradation of degenerated MBP and
resulted in accumulation of non-functional MBP in WM. Female patients also displayed down-regulation of ATP sub-
units and cytochromes, suggesting increased severity of mitochondria impairment in women.
Conclusions: Our study demonstrates that gender-linked modulation of white matter and mitochondria proteomes
influences neuropathology of the temporal lobe in AD + CVD.
Keywords: Alzheimer’s disease, Cerebrovascular disease, Dementia, Temporal lobe, White matter, Citrullination,
Deamidation, Proteomics, iTRAQ
Background
Dementia prevalence and severity in women are sig-
nificantly higher than in men after controlling for ex-
pected lifespans [1, 2], but the neuropathological basis
of this gender bias is currently unknown. Alzheimer’s
disease is the most common form of dementia in the
elderly, the majority of whom also undergo variable
cerebrovascular disease (AD + CVD) [3]. Affected in-
dividuals display a complex brain pathology character-
ized by senile plaques with microinfarcts, as well as a
poorly understood degeneration of the small vessels
that supply blood to the brain [4–7]. While vascular
involvement appears to be closely linked with the
extent of white matter (WM) pathology [8–10], it re-
mains poorly defined how small vessel disease influ-
ences the clinical course of AD + CVD.
Restriction of blood flow to the brain results in WM
tissue damage, leading to neurodegeneration and even-
tual dementia [11–15]. WM pathology contributes to
cognitive impairment and long-term disability in elderly
subjects via multiple mechanisms that do not depend on
amyloid formation [16, 17]. Indeed, brain WM exhibits a
complex composition of different molecules that can be
modified to influence brain function, including both
lipid molecules and proteins such as 2′,3′-cyclic nucleo-
tide 3′-phosphodiesterase (CNP), myelin proteolipid
protein (PLP), and myelin basic protein (MBP) [18].
CNP and PLP, are involved on the maturation of oligo-
dendrocytes [19, 20], while MBP regulates myelination
and initiates essential signaling pathways in brain cells
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[21]. Brain MBP is known to be susceptible to degenera-
tive protein modifications (DPMs) including deamida-
tion and citrullination [22, 23], and myelin degeneration
can directly impair cognitive function due to disruption
of neuronal circuits [24, 25], but the molecular profile of
brain myelin proteins in AD + CVD has yet to be
deciphered.
Degeneration of myelin sheaths causes axon disinte-
gration, leading to impaired mitochondrial function and
decreased provision of the essential molecules needed to
maintain WM integrity [26–28]. Previous studies have
also identified that changes in the molecular compos-
ition of MBP influence white matter pathology in vascu-
lar dementia (VaD) [15, 22, 29], and that excess DPMs
promote proteinopathy and neurodegeneration in both
AD and VaD [30]. However, it remains unclear to what
extent white matter pathology depends on DPM-
induced proteinopathy in AD-related human dementias.
Intriguingly, a previous study reported gender-specific
differences on the accumulation of deamidation in ro-
dent brain proteins [31]. Similarly, prevalence and sever-
ity of citrullination-associated diseases in the central
nervous system is significantly higher in women than in
men [32] what suggests that these two DPMs could
also underpin the increased dementia risk observed in
human females. We therefore used discovery-driven
quantitative proteomics [33] to investigate the mo-
lecular basis of gender influences on the pathology of
AD + CVD.
Results
White matter pathology is influenced by gender in AD +
CVD
In order to assess the molecular basis of gender influ-
ences on risk of Alzheimer’s disease with cerebrovascular
disease (AD + CVD), we first assessed the extent of mye-
lin rarefaction/density loss in post-mortem brain tissues
from male and female patients.
While there were no gender-specific differences noted dur-
ing post-mortem evaluation of brain myelin density in AD+
CVD (Table 1), analysis of the temporal lobe proteome of de-
mentia patients revealed significant up-regulation of myelin
proteins CNP, PLP and hyaluronan proteoglycan 2 (HPLN2),
which were further increased only in female patients (Fig. 1a,
Additional file 1: Table S1). PLP enrichment in the temporal
lobe of female AD+CVD was also validated in another inde-
pendent cohort by western blot (Fig. 1b and c).
Intriguingly, we observed down-regulation of the
myelin-associated protein Cathepsin D in women with
dementia while the rest of myelin proteins identified in
that group were significantly upregulated (Fig. 1a). Fur-
thermore, the protein neural cell adhesion molecule
(NCAM1) involved on functional response to white
matter injury was only up-regulated in male patients
(Fig. 1a). These data indicated that unbiased quantitative
profiling of the human brain proteome can detect
gender-specific differences in white matter pathology
from patients with AD + CVD that were not apparent
from conventional post-mortem evaluation.
The brain protein myelin associated glycoprotein
(MAG) is highly susceptible to ischemia-induced deg-
radation and its levels do not vary in the mammal’s brain
by the effect of gender [34]. Similarly, PLP positively cor-
relates with severity of white matter pathology in small
vessel disease [35], hence MAG/PLP ratio can be used
as a proxy measure of disease severity in affected pa-
tients [35, 36]. Using this approach in our dementia
samples, we observed that MAG/PLP ratio was signifi-
cantly lower in females (0.2) than in males (0.5), indicat-
ing greater severity of WM pathology in women with
AD + CVD. Since both genders exhibited comparable ex-
pression levels of MAG protein, which is readily de-
graded under ischemic conditions [35], these data
suggested that both men and women may undergo a
similar extent of ischemic injury in AD + CVD, but that
subsequent effects on the myelin proteome and PLP ex-
pression differ between genders.
Sex-influenced modification of myelin basic protein in
AD + CVD
Degenerative protein modifications (DPMs) including
deamidation and citrullination are thought to underpin
loss of protein function in the brains of dementia pa-
tients [37–40], so we next assessed whether protein
modification profiles differed between male and female
AD + CVD. To do this, we performed functional prote-
omic analysis by studying the quantitation iTRAQ re-
porter area of all modified peptides for each identified
peptide of the BA21 brain proteome. Using our unbiased
discovery approach, we identified that myelin basic pro-
tein (MBP) exhibited the most extensive occurrence of
DPMs in whole proteome of AD + CVD subjects as
mapped in Fig. 2a. Stoichiometry of deamidation at glu-
tamine (Gln) and asparagine (Asn) residues covered
~30 % of all identified MBP constituent peptides
(Fig. 2b). When compared with controls, AD + CVD pa-
tients exhibited increased ratio of deamidation in brain
MBP, and this was more extensive in women than in men
(Fig. 2c and d), particularly at residues Gln 281, 255, 236
and 215 (Fig. 2e), suggesting increased incidence of DPMs
in women with dementia. Consistent with this concept,
we also observed significantly higher deamidation of Asn
217 in brain MBP only in female AD+CVD patients
(Fig. 2f). Further stoichiometric analysis revealed that
citrullination of arginine (Arg) residues affected ~12 %
percent of MBP constituent peptides in AD+CVD
(Fig. 2g), and we detected hyper-citrullinated MBP only
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Table 1 Demographic and clinical data of dementia subjects and age-matched control subjects. 1. Post-mortem delay
Age-matched control subjects
Gender Age PMa delay Cognitive assessment Cog. exam. Braak CERAD Neuropathology
M 72 17 Normal control Retrospective Interview 1 Sparse Mild AD-like pathology
M 75 20 Normal control Retrospective Interview 0 None Scattered microinfarcts (in right hemisphere: hippocampal CA2/3,
putamen, caudate, external medullary lamina) and SVD: Foci of
arteriosclerosis mainly in white matter
F 68 75 Normal control Retrospective Interview 1 Sparse Mild cerebral amyloid angiopathy. A right frontal microinfarct and
small lacunar infarct in the left putamen. Infarcts in both cortex and
basal ganglia
F 78 23 Normal control Retrospective Interview 2 Sparse Mild AD-like pathology
F 82 26 Normal control Retrospective Interview 0 N.A. No detected AD or CVD pathology
F 87 14 Normal control Retrospective Interview N.A. N.A. Low mean density of neocortical tangles = 2.5 per mm2.
F 99 19 Normal control Retrospective Interview N.A. None No detected AD or CVD pathology
F 86 40 Normal control Retrospective Interview 1 N.A. No detected AD or CVD pathology
F 75 31 Normal control Retrospective Interview N.A. N.A. No detected AD or CVD pathology
F 81 51 Normal control Retrospective Interview N.A. N.A. No detected AD or CVD pathology
Mean 80.3 ± 8.9 31.6 ± 19
AD + CVD subjects
Gender Age PMa delay Cognitive assessment Cog. exam. Braak CERAD Neuropathology
M 83 71 1 y. cog imp. M.M.S.E = 18 4 Moderate Mixed pathology - AD and SVD (predominantly microinfarcts in
frontal lobe & perivascular lacunae in basal ganglia). Cavernous
hemangioma in right ventrolateral posterior centrum semiovale.
Loss of myelin in brain capsules.
M 72 29 7 y. cog imp. M.M.S.E = 20 4 Frequent Mixed AD and CVD. Microinfarcts in putamen. Loss of myelin in
internal capsule
M 84 42 8 y. cog imp. M.M.S.E = 13 5 N.A. Mixed pathology AD with vascular dementia and severe cerebral
amyloid angiopathy.
M 82 38 1 y. dementia M.M.S.E = 16 6 N.A. Mixed pathology AD with old infarcts in the temporal cortex right
hemisphere. CVD affecting parietal and occipital lobes. Microinfarcts
in caudate and putamen. Focal loss of myelin in brain capsules.
M 64 24 1 y. dementia M.M.S.E = 20 N.A. N.A. Mixed pathology AD + CVD affecting middle temporal gyrus,
parietal and occipital lobes. Myelin affectation in brain capsules.
Mean 77 ± 8.7 41 ± 18
F 93 18 2 y. dementia S.I.B = 75/100 5 Frequent Mixed pathology AD + CVD affecting parietal and temporal lobes.
Myelin affectation in brain capsules.
F 89 72 4 y. cog. imp. M.M.S.E = 16 4 N.A. Mixed pathology AD + CVD affecting temporal lobes and brainstem.
Severe myelin affectation in medial and internal temporal gyrus.
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Table 1 Demographic and clinical data of dementia subjects and age-matched control subjects. 1. Post-mortem delay (Continued)
F 89 32 3 y. cog. imp. M.T.S = 5/37 5 N.A. Mixed pathology AD + CVD. Severe changes in hippocampus.
Neurofibrillary tangles in raphe nucleus.
F 92 12 5 y. dementia M.M.S.E = 20 5 N.A. Mixed pathology AD + CVD affecting middle temporal gyrus and
parietal/occipital lobes. Severe myelin affectation in temporal cortex.
F 86 99 2 y. dementia M.M.S.E = 20 6 N.A. Mixed pathology AD + CVD. Moderate temporoparietal infarcts.
Mean 89.8 ± 2.8 46.6 ± 37.5
aPost-mortem delay
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in female patients (Fig. 2h). Citrullination of Arg residue
256 was significantly increased in women with dementia
(Fig. 2i), which also displayed extensive citrullination of Arg
residues 159 and 231, whereas DPM of these residues did
not differ between male dementia patients and controls
(Fig. 2i). These data suggested that women with AD+CVD
exhibit significantly higher brain protein DPMs than male
patients or controls.
Sex-influenced degradation of myelin basic protein in AD
+ CVD
Since WM pathology in AD and VaD is associated with
accumulation of degenerated MBP (dMBP) [15], we next
assessed whether the sex-specific DPMs detected here
could influence the degradation profile of brain MBP. In
dMBP, the protein sequence QDENPVV (residues 82–
88) is susceptible to degradation by cathepsin D due to
the 3D structure of dMBP and generates the byproduct
peptide TQDENPVVHF (residues 81–90) [41–43]. We
therefore assessed whether women and men with AD +
CVD exhibited differential deamidation of Gln residue
82 in the exposed region of dMBP. Using this approach,
we observed that women with dementia displayed
increased stoichiometry of deamidation in Gln 82, which
was associated with impaired degradation of this protein
region (Fig. 3a) and accumulation of dMBP. These data
suggested that dMBP due to Gln deamidation may be
more resistant to proteolytic cleavage similar to other
proteins reported previously [30, 44] and to removal
from brain tissues of female AD + CVD patients. In con-
trast, AD + CVD patients did not exhibit any change on
the degradation ratio of the cathepsin D byproduct YLA-
TASTMDHAR#, despite that increased level of peptide
citrullination was detected for this byproduct in women
with dementia (Fig. 3b). These data indicated that sex-
specific degradation of brain proteins in AD + CVD var-
ies across the proteome in BA21, with MBP being the
most heavily modified protein in the brain of female
with dementia.
Female AD + CVD is associated with specific modifications
of the temporal lobe and mitochondria proteomes
Women with cognitive disorders have been reported to
display impaired glutamine-glutamate metabolism in the
brain [45, 46], and may exhibit mitochondria dysfunc-
tion associated with defective hormone signaling [47], so
Fig. 1 a Heatmap displaying protein enrichment/depletion in the white matter proteome of male and female AD + CVD subjects compared to
age-matched controls. Log ratios in AD + CVD subjects were normalized to controls (controls ratio = 1). Red values represent protein enrichment,
blue values represent protein depletion and white values indicate no change in the ratio scale. Protein names were listed on the right side of
each heat map line. Significance level of modified proteins in each group were indicated at the upper right corner of each box (* p < 0.05 and
gender difference≥ 0.2; ** p < 0.001 and gender difference ≥ 0.9). Tabular data of values shown in this heat map can be found in Additional file 1:
Table S1. b Validation of the PLP enrichment in the temporal lobe of AD + CVD women was confirmed by Western blot in individual subjects from an
independent cohort. c Densitometry analysis of Western blot signal normalized by Ponceau intensities. Significance level in graph of PLP signal in
women relative to controls (* p < 0.05)
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Fig. 2 (See legend on next page.)
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we next sought to identify sex-specific modulation of the
temporal lobe and mitochondria proteomes in AD +
CVD. Whole temporal lobe proteome displayed in-
creased levels of Gln deamidation in AD + CVD subjects
relative to age-matched controls (3.90 % female demen-
tia, 3.87 % male dementia, 3.52 % age-matched controls;
chi square 27.698 with one degree of freedom, p-value
<0.001) and in female patients we detected increased
levels of the enzyme carbonyl reductase 1 (NADPH1)
compared with either male patients or controls (iTRAQ
ratio female/controls 2.09 ± 0.13; p-value <0.001; gender
ratio female/male 2.36). Since NADPH1 can promote
deamidation of Gln residues [48], and we detected a re-
duction in glutamine synthetase (GS) levels in women
with dementia (iTRAQ ratio female/controls 0.5 ± 0.09;
p-value 0.002; gender ratio female/male 0.45), these data
could explain the impaired glutamine-glutamate metab-
olism identified in the temporal lobe of female dementia
patients. Indeed, we also found numerous gender-
specific deamidations of various Gln amino acid pairs
and a single asparagine amino acid pair in the temporal
lobe of AD + CVD subjects (Fig. 4a and b). We also ob-
served increased citrullination of Arg residues in female
AD + CVD patients compared with male patients, but
only at a limited number of amino acid pairs (Fig. 4c).
Dementia pathology is strongly associated with mito-
chondrial production of reactive oxidative species (ROS),
and in our AD+CVD samples we detected up-regulation
of the dismutase protein superoxide dismutase-1 as well as
down-regulation of aldehyde dehydrogenase and mitochon-
drial creatine kinase-U-type relative to controls (Fig. 5,
Additional file 2: Table S2). While evidence of mitochondria
dysfunction was apparent in both men and women with de-
mentia, female patients also exhibited dysregulation of the
D and O subunits of ATP synthase, together with down-
regulation of cytochromes, NADH ubiquinone alpha sub-
units (5 and 8) and chaperone stress-70 (Fig. 5, Additional
file 2: Table S2), indicating that perturbation of the mito-
chondria proteome in AD+CVD is more pronounced in
women than in men. Together, these data confirm a
positive association between WM pathology and mitochon-
dria dysfunction in the temporal lobe of AD +CVD sub-
jects, and suggest that dysregulation of mitochondrial ATP
synthesis; redox activity and cytochrome function represent
gender-specific neurodegenerative processes in AD+CVD.
Discussion
In the current study, we used discovery-driven quan-
titative proteomics to uncover gender influences on
myelin neuropathology and dysfunctional mitochon-
dria proteomes in the temporal lobe of patients with
AD + CVD. The data from this study provide novel
insight into the molecular basis of the increased de-
mentia risk and disease severity observed in women
that develop AD + CVD.
Despite that post-mortem evaluation of myelin density
failed to detect gender differences on white matter path-
ology in patients with AD+CVD, the data from quantita-
tive profiling of the brain proteome clearly revealed the
gender-specific molecular pathology of the affected WM.
While we detected similar levels of MAG protein in men
and women with dementia, suggesting a comparable ex-
tent of ischemic injury in both genders based on MAG/
PLP ratio [35, 36], the severity of WM pathology observed
in women was greater than that observed in men. Accu-
mulation of dMBP in the temporal lobe is a key indicator
of WM pathology in dementia [15, 49]. In disease settings,
hyper-citrullination of MBP is thought to increase protein
degradation by cathepsin D and other enzymes, leading to
axonal dysfunction and progressive loss of neuronal func-
tion [43, 50, 51]. In-line with predictions, our functional
proteomics study confirmed that MBP was hyper-
citrullinated in women with dementia, but we also ob-
served an unexpected impairment of dMBP degradation,
which was associated with reduced cathepsin D expression
and increased MBP deamidation at Gln residues (particu-
larly in the degenerative epitope QDENPVV) [15, 41, 42].
Deamidation of Gln residues favors the proteolysis of
dysfunctional proteins via the ubiquitin proteasome
system [52], but Gln deamidation of brain proteins
(See figure on previous page.)
Fig. 2 Degenerative modifications in MBP. a 3D structural modelling of MBP sequence in AD + CVD, showing modified sites including Arg
citrullination and Gln/Asn deamidation. b Stoichiometry of MBP deamidation considering the percentage of all confidentially identified peptides
in all groups (AD + CVD subjects and controls). c Relative level of Gln deamidation considering all the identified sites from the obtained iTRAQ
peak intentities in age-matched controls, AD + CVD women and AD + CVD men. d Relative levels of Asn deamidation considering all the
identified sites from the obtained iTRAQ peak intentisites in age-matched controls, AD + CVD women and AD + CVD men. e Site distribution of
Gln deamidation peak intensities in age-matched controls, AD + CVD women and AD + CVD men. f Site distribution of Asn deamidation peak
intensities in age-matched controls, AD + CVD women and AD + CVD men. g Stoichiometry of MBP citrullination considering the percentage of
all confidentially identified peptides in all groups (AD + CVD subjects and controls). h Relative level of Arg citrullination across all sites based on
the obtained iTRAQ areas in age-matched controls, women with dementia, and men with dementia. i Site distribution of Arg citrullination iTRAQ
area intentities in MBP from age-matched controls, women with dementia, and men with dementia. Significance level in graphs (* p < 0.05;
** p < 0.001)
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including MBP is also strongly associated with protei-
nopathy [51, 53, 54] which may resist the degradation
of dMBP by the ubiquitin proteasome system. This
impaired clearance of dMBP leads to accumulation of
dysfunctional protein in the female brain. Our data
now indicate that gender influences on the dementia-
associated deamidation of MBP may alter protein deg-
radation in the temporal lobe of AD + CVD patients.
We also observed marked up-regulation of several dif-
ferent myelin proteins in the temporal lobe of AD +
CVD subjects, suggestive of an ongoing yet dysfunc-
tional remyelination process [55]. Our data are therefore
consistent with a previous report that WM pathology is
associated with accumulation of HPLN2, which inhibits
axonal remyelination in the brain [55]. Abnormal remye-
lination may also account for the counterintuitive in-
crease in several myelin proteins including CNP and
PLP in the temporal lobe of AD + CVD subjects. Im-
paired remyelination has previously been characterized
to be associated with WM lesions [56], and may also be
a feature of patients with AD + CVD, in whom the puta-
tive remyelination defect was closely associated with Gln
deamidation of MBP.
In a recent study of mice that lack the enzyme L-
isoaspartyl methyltransferase (PIMT) which repairs
damaged proteins, female animals were reported to ex-
hibit greater accumulation of IsoAsp-type DPMs in the
brain [31] . PIMT knock-out mice have also been shown
to exhibit increased deamidation and imbalance of the
glutamate-glutamine cycle in the brain [57]. These data
are consistent with the current report, which suggests
that gender-associated increases on deamidation of spe-
cific brain proteins may contribute to the increased se-
verity of AD + CVD observed in women. While gender
influences on enzymatic citrullination of Arg residues
were less marked than effects on Gln deamidation by
NADPH1, both processes can liberate ammonia bypro-
ducts thought to contribute to WM damage in human
dementia [48, 58]. Accordingly, we also detected in-
creased NADPH1 levels together with down-regulation
of GS in the temporal lobe of women with AD + CVD.
GS are astrocytic enzymes able to efficiently capture free
ammonia during the Gln synthesis in the brain [59, 60].
Down-regulation of GS in the temporal lobe of women
with dementia may indicate abnormal production of Gln
in the brain, in-turn leading to increased expression of
NADPH1 enzymes that enhance production of glutam-
ate from Gln residues. Further research will now be re-
quired to assess this possibility.
Whether mitochondria dysfunction precedes changes
in the WM proteome or vice versa remains unclear.
Other colleagues have reported that an increase in am-
monia byproducts during neurodegeneration can exacer-
bate glutamate toxicity and impair mitochondria
function [61]. Here we observed that AD + CVD patients
displayed down-regulation of mitochondrial kinase-U-
type protein, which is known to be dysregulated in
ischemia-induced mitochondrial impairment [62]. We
further observed that cytochromes and ATP subunits
were significantly altered only in women with AD +
Fig. 3 Degradation of MBP in the temporal lobe of AD + CVD
subjects. Degradation ratio of MBP was calculated based on the
peptide intensity areas in each group showing exact match with
previous reported MBP degradation byproducts by the effect of
cathepsin D (see detailed explanation of that method in the material
and methods section). All ratios were normalized to age-matched
controls (ratio 1 = normal degradation). a Degradation ratio of the
MBP byproduct TQ#DENPVVHF in women and men with dementia.
As shown, higher ratio of Gln deamidation (>2.0) in the MBP
byproduct TQ#DENPVVHF was associated with lower degradation
ratio (<0.5) of the protein in AD + CVD women. b Degradation ratio
of the MBP byproduct YLATASTMDHAR# in women and men with
dementia. MBP degradation ratio of this byproduct in AD + CVD
women (≈1) was not affected by the increased level of
citrullination (ratio ≈ 2.5)
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CVD, consistent with increased severity of mitochondria
dysfunction in this group. According to our findings,
perturbation of the mitochondrial proteome appears to
be proportional to the severity of WM pathology in hu-
man AD + CVD. This result suggests that mitochondria
dysfunction in AD-related disorders may be a product of
early alterations in the WM proteome by vascular dys-
function, hence as recently suggested the vascular com-
ponent of disease is likely to exert a major influence on
the clinical course of human dementias.
Conclusions
While several epidemiological and clinical studies have
showed that women exhibit higher risk of dementia than
men, the molecular neuropathology of this gender differ-
ence remains elusive. In the current study, we used un-
biased quantitative proteomics to assess the molecular
basis of gender influences on risk of AD + CVD. For the
first time, we report sex-specific molecular differences in
white matter pathology and mitochondrial proteomes in
the temporal lobe of AD + CVD patients. In particular,
we observed that hyper-citrullination and hyper-
deamidation of MBP were prevalent in female dementia
patients. Specifically, deamidation of the glutamine resi-
due 82 in the MBP degenerative epitope was associated
with impaired degradation and accumulation of degener-
ated protein in the temporal lobe of women with de-
mentia. This study uncovers the gender influences on
the neuropathology of AD + CVD, and may pave the way
for future clinical interventions that can reduce demen-
tia risk in both male and female patients.
Methods
Brain tissues
Autopsied brain specimens were carefully evaluated for
the presence of senile plaques and CVD at the Newcastle
Fig. 4 Characterization of modified amino acid pairs in whole temporal lobe proteome of AD + CVD subjects and controls. a Relative intensity
areas of deamidated Gln amino acid pairs in the temporal lobe proteome of age-matched controls, women with dementia, and men with
dementia. b Relative intensity areas of deamidated Asn amino acid pairs in the temporal lobe proteome of age-matched controls, women with
dementia, and men with dementia. c Heat map displaying relative intensity areas of Arg citrullination amino acid pairs in whole temporal lobe
proteome of age-matched controls, women with dementia, and men with dementia. In the heat map ratio scale red values indicate up-
regulation of the referred amino acid pair and white values indicate no identification. The following amino acid pairs were not susceptible to Arg
citrullination in the temporal lobe of human subjects; Arg-Cys, Arg-Lys, Arg-Met, Arg-Gln and Arg-Trp. Significance level between AD + CVD and
controls (* p < 0.05; ** p < 0.001)
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Brain Tissue Resource (NBTR, UK). The temporal cortex
region BA21 was used in all experiments (both control
and dementia samples). All dementia brain samples met
histological criteria for AD+CVD, whereas control sub-
jects lacked features of either dementia or AD+CVD.
Brain samples in each experimental group were closely
matched for key variables including post-mortem delay,
cognitive assessment data, age at death, and histological
evaluation (Table 1) [63]. Finally, BA21 tissues for western
blot validation of the PLP level were generously provided
by the Harvard brain tissue resource center (HBTRC). In-
formed consent was obtained from all participants or their
legal representatives. All experimental procedures were
approved by the ethical boards at Nanyang Technological
University (NTU, Singapore) and NBTR, and were per-
formed in accordance with NTU guidelines.
Reagents
All reagents were purchased from Sigma-Aldrich (St.
Louis, MO, USA) unless specified otherwise.
Tissue processing and protein extraction
In order to minimize potential confounding factors and to
efficiently limit the excessive cost of iTRAQ experiments,
we adopted a pooling strategy for our proteomic analyses
[64–66]. Approximately 10 milligrams of brain tissue from
each subject was homogenized in 1 % SDS buffer using the
tissue homogenizer bullet blender (Next Advance, NY,
USA) and then pooled into one of the following three
groups: age-matched controls (10 subjects), male dementia
subjects (5 subjects), and female dementia subjects (5 sub-
jects). Experiments were performed in triplicate, and only
those proteins that were confidently identified in all three
experiments are reported here (see detailed description of
statistical analyses below).
Proteins were acetone-precipitated and quantified by
bicinchoninic acid assay. Two-hundred micrograms of pro-
tein were resolved by SDS-PAGE and visualized using Coo-
massie Blue staining. Protein bands were cut and destained
in 75 % acetonitrile containing 25 mM triethylammonium
bicarbonate (TEAB). Gel cubes were reduced with Tris 2-
carboxyethyl phosphine hydrochloride (5 mM), alkylated
Fig. 5 Heatmap showing ratios of protein enrichment/depletion in the mitochondrial proteome of male and female AD + CVD subjects
compared to age-matched controls. Log ratios in AD + CVD subjcets were normalized to controls (controls ratio = 1). Red values represent protein
enrichment, blue values represent protein depletion and white values indicate no change in the ratio scale. Protein names were listed on the
right side of each heat map line. All proteins reported here are significantly modified versus controls (p < 0.05). Significance level between AD +
CVD groups (* p < 0.05 and gender difference≥ 0.2). Tabular data of values shown in this heat map can be found in Additional file 2: Table S2
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with methyl methanethiosulfonate (10 mM), and then
dehydrated using acetonitrile. Proteins were digested over-
night at 37 °C in sequencing-grade modified trypsin (Pro-
mega, Madison, WI, USA). Peptides were extracted using
50 % acetonitrile in 5 % acetic acid solution under ultra-
sound sonication, then dried and concentrated using a vac-
uum concentrator (Eppendorf AG, Hamburg, Germany).
iTRAQ labelling and shotgun mass spectrometry
Labeling of dried peptides was performed as previously re-
ported [38, 39, 67]. Briefly, 4-plex iTRAQ reagent Multi-
plex kits (Applied Biosystems, Foster City, CA) were used
according to the manufacturer’s protocol. Tags were dis-
tributed as follows; 114 = controls; 116 = women; 117 =
men. The iTRAQ-labeled peptides were desalted using
Sep-Pak C18 cartridges (Waters, UK) and fractionated by
high-performance liquid chromatography (HPLC)
(Shimadzu, Kyoto, Japan) on a PolyWAX LP column
(4.6 × 200 mm, 5 μm, 300 Å) (PolyLC, Columbia, MD,
USA). Buffer A (10 mM ammonium acetate, 85 % aceto-
nitrile, 0.1 % acetic acid) and buffer B (30 % acetonitrile,
0.1 % formic acid) were used to establish a 60 min HPLC-
gradient at 1 ml/min flow rate. Chromatograms were re-
corded at 280 nm. A total of 60 fractions were collected
and subsequently combined into 26 fractions according to
peak intensities.
LC-MS/MS analysis of the brain peptides was per-
formed using a QSTAR Elite mass spectrometer (Applied
Biosystems/MDS Sciex, Foster City, CA, USA) coupled
with online nanoflow multidimensional liquid chromatog-
raphy system (MDLC). A custom-made nanobore C18
column with a picofrit nanospray tip (75 μm ID× 15 cm,
5 μm particles) was used to separate the iTRAQ-labeled
peptides. The QSTAR Elite was set to positive ion mode
using Analyst QS 2.0 software for data acquisition (Ap-
plied Biosystems, Foster City, CA, USA). The precursors
with a mass range of 300–1600 m/z and calculated
charge from +2 to +5 were selected for fragmenta-
tion. Peptides above a 5-count threshold were selected
for MS/MS and each selected target ion was dynamic-
ally excluded for 20 s with a mass tolerance of
0.1 Da. Smart information-dependent acquisition was
activated with automatic collision energy and auto-
matic MS/MS accumulation. The fragment intensity
multiplier was set to 20, and the maximum accumula-
tion time was 2 s.
LC-MS/MS data search
MS/MS data searching was performed using the
concatenated target-decoy Uniprot database in ProteinPi-
lot software 3.0 (revision number 114732; Applied Biosys-
tems, Foster City, CA, USA) with Paragon (3.0.0.0,
113442) and Pro Group algorithms implemented. Diges-
tion enzyme was set as semi-trypsin. User-defined
parameters and false discovery rate (FDR) for assignation
of peptides and proteins in the software were set as
previously specified [38]. Briefly FDR <1 % (FDR =
2.0 × [decoy hits/total hits] × 100 %) and unused Protein
Score value ≥2 were used as qualification criteria (corre-
sponding to a confidence limit of 99 %). These criteria en-
abled the identification of over 2400 total proteins.
Regulation of protein levels and statistical inference
The Pro Group algorithm in Protein Pilot was used to
automatically calculate the iTRAQ reporter ratio for each
protein based on error factor and p-value; Error factor =
10 95% confidence error where 95 % confidence error = SMW ×
(Student’s t factor for n – 1° of freedom). SMW refers to
weighted standard deviation of the weighted average of
log ratios, and n refers to number of peptides contributing
to protein relative quantification. P-values were deter-
mined by calculating Student’s t factor where t = (weighted
average of log ratios − log bias) divided by weighted stand-
ard deviation; which allowed determination of p-value
with n − 1° of freedom. The statistical criteria used by
Paragon and Pro Group algorithms in Protein Pilot have
been described in detail elsewhere [68, 69]. Regulation
cut-offs to identify protein differential expression between
dementia groups and controls were established based on
the calculated percentage coefficient of variation (% CV)
of the protein ratios. A total 95 % of the proteins identified
in our study displayed a ratio % CV <50 % (Additional file
3: Figure S1A). Accordingly, we set the ratio threshold at
>1.5 for protein up-regulation and at <0.67 (1/1.5) for pro-
tein down-regulation. No significant differences were ob-
served for % CV of ratios between the male and female
dementia groups, indicating successful control of outliers
in each respective pool. Furthermore, no significant differ-
ences were observed in postmortem delay mean confi-
dence intervals between experimental groups (Additional
file 3: Figure S1B). In order to increase confidence in de-
tecting changes in protein expression level, we then com-
bined these data with a G-test calculation [70] for each
protein using only those contributor peptides identified
with ≥ 99 % of confidence. G-values were calculated as
follows:
G ¼ 2 ðCtrlA  ln CtrlA  CtrlA þ DemAð Þ  2ð Þ½ 
þ DemA  ln DemA  CtrlA þ DemAð Þ  2ð Þ½ Þ
In this equation, CtrlA refers to iTRAQ reporter area in
the control group, DemA refers to iTRAQ reporter area of
the respective dementia group, and ‘ln’ refers to the nat-
ural logarithm. G-values fit well to the x2 distribution with
one degree of freedom [66], and accordingly, we were able
to calculate the corresponding p-value for each G-value
obtained. Finally, the calculated p-values were corrected
for multiple comparisons using the Benjamini-Hochberg
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FDR correction at 0.05α [71] to obtain a corrected p-value
of 0.014. Following this approach, we considered only
those proteins confidently identified in all three experi-
ments (i.e. those containing at least one unique peptide
identified with >99 % confidence in each group, and dis-
playing a G-test p-value lower than 0.014). A total of 321
proteins satisfied these stringent criteria (Additional file 4)
and (Additional file 3: Figure S1C). We then assessed the
influence of gender on expression of the 321 proteins
identified by analyzing the %CV of the iTRAQ ratios in
both the male and female dementia groups. The cut-off
for protein differential expression between men and
women with dementia was set at ≥0.2 (based on %CV
<20 % ([116:114] – [117:114]) (Additional file 3: Figure
S1D). Combining all the statistical approaches described
above, we observed that a total of 59 proteins were signifi-
cantly modulated in the dementia groups compared with
controls (Additional file 5), including 38 proteins that
were differentially expressed between male and female de-
mentia patients (Additional file 6).
Quantification of peptide modifications and statistical
inference
To confidently quantify the level of modified peptides in
our profiled AD+CVD brain tissues we assessed influence
of age and disease on the increase of deamidation and
citrullination in temporal lobe proteins performing spectral
counting in peaks [72]. This analysis confirmed the exacer-
bate increase of DPTMs in temporal lobe proteins as a
disease-associated process (Additional file 3: Figure S1E
and S1F). Analysis of modified peptides (deamidation and
citrullination) was performed using unique peptide iTRAQ
reporter peak areas. Only those peptides identified with ≥
99 % confidence were included in this analysis. Mean
peptide reporter peak areas in each of the three groups
(age-matched controls, men with dementia, women with
dementia) were compared by One-Way ANOVA, and p-
values were corrected for multiple comparisons using Bon-
ferroni. Data were reported as mean and SD unless stated
otherwise.
Molecular bioinformatics and MBP functional proteomics
MitoMiner was used for analysis of the mitochondria
proteome [73]. I-Tasser suite [74] was used for MBP mod-
elling, and Pymol was used to render the 3D structure of
the protein [75]. Using previously reported LC-MS/MS
data on the byproducts of bovine MBP degradation [43],
we performed functional proteomics to investigate the
degradation profile of MBP in the temporal lobe of AD+
CVD post-mortem brain tissues. Initially, pairwise align-
ment between bovine and human MBP sequences was
performed using EMBOSS Needle [76] (Additional file 7:
Figure S2). Semi-trypsin was enabled during database
search. Two criteria were applied to detect MBP peptides
as degradation byproducts: (1) an “exact match” between
the identified peptide and the peptide obtained by pairwise
alignment, and (2) the presence of modified Lys/Arg at
the terminal sites of the peptides (thereby rejecting the
tryptic-digested peptides generated during sample
processing). Using these criteria, the MBP degradation
byproducts TQDENPVVHF and YLATASTMDHAR# (#
referring to Arg citrullination) were identified with ≥99 %
confidence. MBP percentage degradation was calculated
using the following equation:
Total iTRAQ reporter area }exact match}  100
Total iTRAQ reporter area }exact match} þ
Total iTRAQ reporter area }partial match}
In this equation, “exact match” refers to the identified
MBP degradation byproducts described above. “Partial
match” refers to longer tryptic peptides that included
the exact match sequence of the degradation byproducts.
Total iTRAQ reporter area refers to the sum of all iden-
tified iTRAQ reporter peak areas for the peptide. The
calculation was performed in each group including age-
matched controls, women with dementia, and men with
dementia. Finally, the degradation ratio was obtained by
dividing the MBP percentage degradation values for the
women and men dementia groups by that calculated for
age-matched controls.
Western blot
Tissues from two AD+CVD women (68y and 79y respect-
ively), two AD+CVD men (74y and 63y respectively), one
male control (77y) and one female control (77y) were ho-
mogenized as described above in 1 % SDS buffer. Western
blot was performed as previously reported [77]. Briefly, pro-
teins were reduced by 2-mercaptoethanol (5 %) in 95 °C
during five minutes and subsequently mixed with BioRad
2× Laemmli sample buffer (CA, USA). Protein amount was
quantified by Bradford assay and equal amount of protein
was loaded in a 15 % SDS-PAGE gel. Resolved proteins
were then blotted onto a nitrocellulose membrane and de-
tected using the polyclonal goat anti-PLP (SC-23570) pri-
mary antibody (1:1000 dilution) and the rabbit anti-goat
(SC-2768) secondary antibody (1:3000 dilution). Ponceau
staining was used as loading control [78]. Densitometry of
Western blot signal was mesured using ImageJ (Rasband
W.S., ImageJ. U.S. National Institutes of Health, MD.,
U.S.A. http://imagej.nih.gov/ij/ 1997-2016) and Student's t-
test analysis of data was performed.
Data deposition
Proteomics data have been made publicly available
through ProteomeXchange consortium [79] via the part-
ner repository PRIDE under the following identifier
PXD003027.
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